These findings were confirmed by a meta-analysis of randomized trials comparing erlotinib/gefitinib monotherapy or the combination of erlotinib/gefitinib and chemotherapy with chemotherapy alone or placebo in patients with sensitizing EGFR mutation-positive-NSCLC, which showed a delayed disease progression when the treatment included gefitinib/erlotinib, but no effect on OS (107). This evidence concerns the gene EGFR and non-small cell lung carcinoma.